Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11409076 | 0.81 | CA12 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5035464 | 0.80 | GPR3 (0.38) | MAPTCYP1A2NPC1RAB9AALDH1A1 | |
| SCHEMBL6297073 | 0.77 | CA12 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5038852 | 0.77 | HTR1A (0.33) | CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL3136387 | 0.77 | HTT (0.37) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10564377 | 0.77 | CA12 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL224709 | 0.74 | GSTP1 (0.53) | CYP1A2CYP2A6CYP1A1CYP1B1NPC1 | |
| SCHEMBL6851412 | 0.73 | AR (0.40) | MAPTALDH1A1KDM4E | |
| SCHEMBL30548757 | 0.72 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4992020 | 0.72 | CA1 (0.50) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336133-A1 | Purine analogs having HSP90-inhibiting activity | Conforma Therapeutics Corporation (US) | 2011-06-22 | — | — | EP | disclosed |
| CN-101505762-A | Orally active purinyl inhibitors of heat shock protein 90 | CONFORMA THERAPEUTICS CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080125446-A1 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-7241890-B2 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20050049263-A1 | Purine analogs having hsp90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-03-03 | — | — | US | disclosed |
| EP-1440072-A4 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTIC CORP (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1440072-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | Conforma Therapeutic Corporation (US) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037860-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTICS CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125446-A1 | Purine analogs having HSP90-inhibiting activity | HSP90B1, HSP90AB1, HSP90AA1 | CA1 4635/4885CA2 4385/4885CA7 4863/4885 |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | CA1 4522/4885CA2 4080/4885CA7 4842/4885 |
| US-20050049263-A1 | Purine analogs having hsp90-inhibiting activity | HSP90B1, HSP90AB1, HSP90AA1 | CA1 4635/4885CA2 4385/4885CA7 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.